29/04/2026 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 3.2 million subscribed by a limited number of investors Download PDF Post navigationPreviousPrevious post:AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditorsNextNext post:Annual financial results as of 31 December, 2025Related PostsAnnual financial results as of 31 December, 202513 May 2026AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026Update on clinical development program16 April 2026AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS24 February 2026FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®9 February 2026
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026
New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS24 February 2026
